Potential uptake and correlates of willingness to use a supervised smoking facility for noninjection illicit drug use

Journal of Urban Health

Volumn 82, Issue 2, 2005, Pages 276-284

  Collins, Courtney L C ^a   Kerr, Thomas ^a,c   Kuyper, Laura M ^a   Li, Kathy ^a   Tyndall, Mark W ^a,b   Marsh, David C ^a   Montaner, Julio S ^a,b   Wood, Evan ^a,b  

^a ST PAUL S HOSPITAL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c Canadian HIV/AIDS Legal Network   (Canada)

Author keywords

Harm reduction; HCV; HIV; Supervised smoking facilities

Indexed keywords

COCAINE; DIAMORPHINE; METHAMPHETAMINE;

ADULT; ARTICLE; CANADA; DEMOGRAPHY; DRUG OVERDOSE; DRUG USE; FEMALE; FOLLOW UP; HEALTH CARE FACILITY; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUESTIONNAIRE; SMOKING; SUICIDE;

ADULT; ATTITUDE TO HEALTH; BRITISH COLUMBIA; COCAINE-RELATED DISORDERS; COHORT STUDIES; COMMUNITY HEALTH CENTERS; FEMALE; HEPATITIS C; HEROIN DEPENDENCE; HIV INFECTIONS; HUMANS; LOGISTIC MODELS; MALE; METHAMPHETAMINE; MIDDLE AGED; QUESTIONNAIRES; RISK-TAKING; SMOKING; STREET DRUGS; SUBSTANCE ABUSE TREATMENT CENTERS; SUBSTANCE-RELATED DISORDERS; URBAN HEALTH SERVICES;

EID: 24044498936     PISSN: 10993460     EISSN: None     Source Type: Journal    
DOI: 10.1093/jurban/jti051     Document Type: Article

References (41)

1. Strathdee SA, Galai N, Safaeian M, et al. Sex differences in risk factors for HIV seroconversion among injection drug users: a ten year perspective. Arch Intern Med. 2001;161:1281-1288.
2. Craib KJ, Spittal PM, Wood E, et al. Risk factors for elevated HIV incidence among Aboriginal injection drug users in Vancouver. CMAJ. 2003;168:19-24.
3. van Beek I, Dwyer R, Dore GJ, Luo K, Kaldor JM. Infection with HIV and hepatitis C virus among injecting drug users in a prevention setting: retrospective cohort study. BMJ. 1998;317:433-437.
4. Thorpe LE, Quellet LJ, Levy JR, Williams IT, Monterroso ER. Hepatitis C virus infection: prevalence, risk factors, and prevention opportunities among young injection drug users in Chicago, 1997-99. J Infect Dis. 2000;182:1588-1594.
5. Thorpe LE, Quellet LJ, Hershow R, et al. Risk of hepatitis C virus infection among young adult injection drug users who share injection equipment. Am J Epidemiol. 2002;155:645-653.
6. Selvey LA, Denton M, Plant AJ. Incidence and prevalence of hepatitis C among clients of a Brisbane methadone clinic: factors influencing hepatitis C serostatus. Aust N Z J Public Health. 1997;21:102-104.
7. Hahn JA, Page-Shafer K, Lum PJ, Ochoa K, Moss AR. Hepatitis C virus infection and needle exchange use among young injection drug users in San Francisco. Hepatology. 2001;34:180-187.
8. Hagan H, Thiede H, Weiss NS, Hopkins SG, Duchin JS, Alexander ER. Sharing of drug preparation equipment as a risk factor for hepatitis C. Am J Public Health. 2001;91:42-46.
9. Villano SA, Vlahov D, Nelson KE, Lyles CM, Cohn S, Thomas DL. Incidence and risk factors for hepatitis C among injection drug users in Baltimore, Maryland. J Clin Microbiol. 1997;35:3274-3277.
10. Tortu S, Neaigus A, McMahon J, Hagen D. Hepatitis C among noninjecting drug users: a report. Subst Use Misuse. 2001;36:523-534.
11. Flamm SL, Parker RA, Chopra S. Risk factors associated with chronic hepatitis C virus infection. Limited frequency of an unidentified source of transmission. Am J Gastroenterol. 1998;93:597-600.
12. Tortu S, McMahon JM, Pouget ER, Hamid R. Sharing of noninjection drug-use implements as a risk factor for hepatitis C. Subst Use Misuse. 2004;39:211-224.
13. Conry-Cantilena C, VanRaden M, Gibble J, et al. Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection. N Engl J Med. 1996;334:1691-1696.
14. Alter HJ, Conry-Cantilena C, Melpolder J, et al. Hepatitis C in asymptomatic blood donors. Hepatology. 1997;26:29S-33S.
15. Broadhead RS, van Hulst Y, Heckathorn DD. The impact of a needle exchange's closure. Public Health Rep. 1999;114:439-447.
16. Haemmig R. Beyond safe injecting rooms: next steps in hard reduction incl. safe smoking rooms. Paper presented at: International Conference on the Reduction of Drug Related Harm; April 20-24, 2004; Melbourne, Australia.
17. Wood E, Kerr T, Small W, Li K, Marsh DC, Montaner JS, Tyndall MW. Changes in public order after the opening of a medically supervised safer injecting facility for illicit injection drug users. CMAJ. 2004 Sep 28; 171(7):731-734.
18. Kerr TH, Wood E, Palepu A, Wilson D, Schechter MT, Tyndall MW. Responding to explosive HIV epidemics driven by frequent cocaine injection: is there a role for safer injecting facilities? Journal of Drug Issues. In press.
19. Kerr T, Palepu A. Safe injection facilities in Canada: is it time? CMAJ. 2001;165:436-437.
20. Wood E, Kerr T, Spittal PM, et al. The potential public health and community impacts of safer injecting facilities: evidence from a cohort of injection drug users. J Acquir Immune Defic Syndr. 2003;32:2-8.
21. Wood E, Spittal PM, Small W, et al. Displacement of Canada's largest public illicit drug market in response to a police crackdown. CMAJ. 2004;170:1551-1556.
22. Campbell L. Four Pillars-the Vancouver experience. Paper presented at: 15th International Conference on the Reduction of Drug Related Harms; April 22, 2004; Melbourne, Australia.
23. Wood E, Schechter MT, Tyndall MW, Montaner JS, O'Shaughnessy MV, Hogg RS. Antiretroviral medication use among injection drug users: two potential futures. AIDS. 2000;14:1229-1235.
24. Wood E, Tyndall MW, Spittal PM, et al. Unsafe injection practices in a cohort of injection drug users in Vancouver: could safer injecting rooms help? CMAJ. 2001;165:405-410.
25. Spittal PM, Craib KJ, Wood E, et al. Risk factors for elevated HIV incidence rates among female injection drug users in Vancouver. CMAJ. 2002;166:894-899.
26. Wood E, Tyndall MW, Spittal PM, et al. Factors associated with persistent high-risk syringe sharing in the presence of an established needle exchange programme. AIDS. 2002;16:941-943.
27. Miller CL, Johnston C, Spittal PM, et al. Opportunities for prevention: hepatitis C prevalence and incidence in a cohort of young injection drug users. Hepatology. 2002;36: 737-742.
28. Spittal PM, Bruneau J, Craib KJ, et al. Surviving the sex trade: a comparison of HIV risk behaviours among street-involved women in two Canadian cities who inject drugs. AIDS Care. 2003;15:187-195.
29. Sterk CE, Theall KP, Elifson KW. Who's getting the message? Intervention response rates among women who inject drugs and/or smoke crack cocaine. Prev Med. 2003; 37:119-128.
30. Rosse RB, Collins JP Jr, Fay-McCarthy M, Alim TN, Wyatt RJ, Deutsch SI. Phenomenologic comparison of the idiopathic psychosis of schizophrenia and drug-induced cocaine and phencyclidine psychoses: a retrospective study. Clin Neuropharmacol. 1994;17: 359-369.
31. Colliver JD, Kopstein AN. Trends in cocaine abuse reflected in emergency room episodes reported to DAWN. Drug abuse warning network. Public Health Rep. 1991;106:59-68.
32. Bailey I. Pickton accused in 4 more deaths: this is now the largest serial killer investigation in Canadian history. National Post. October 3, 2002:A1.
33. Astemborski J, Vlahov D, Warren D, Solomon L, Nelson KE. The trading of sex for drugs or money and HIV seropositivity among female intravenous drug users. Am J Public Health. 1994;84:382-387.
34. Krai AH, Bluthenthal RN, Lorvick J, Gee L, Bacchetti P, Edlin BR. Sexual transmission of HIV-1 among injection drug users in San Francisco, USA: risk-factor analysis. Lancet. 2001;357:1397-1401.
35. Kilbourne AM, Herndon B, Andersen RM, Wenzel SL, Gelberg L. Psychiatric symptoms, health services, and HIV risk factors among homeless women. J Health Care Poor Underserved. 2002;13:49-65.
36. Faruque S, Edlin BR, McCoy CB, et al. Crack cocaine smoking and oral sores in three inner-city neighborhoods. J Acquir Immune Defic Syndr Hum Retrovirol. 1996;13:87-92.
37. Mitchell-Lewis DA, Phelan JA, Kelly RB, Bradley JJ, Lamster IB. Identifying oral lesions associated with crack cocaine use. J Am Dent Assoc. 1994;125:1104-1108, 1110.
38. Porter J, Bonilla L. Crack users' cracked lips: an additional HIV risk factor. Am J Public Health. 1993;83:1490-1491.
39. Centers for Disease Control and Prevention. Top 11 most frequently asked questions about viral hepatitis. Available at: http://www.cdc.gov/ncidod/ diseases/hepatitis/common_faqs.htm. Accessed June 15, 2004.
40. From the Centers for Disease Control and Prevention. 1993 revised classification system for HIV, infection and expanded surveillance case definition for AIDS, among adolescents and adults. JAMA. 1993;269:729-730.
41. Barr CE, Lopez MR, Rua-Dobles A, Miller LK, Mathur-Wagh U, Turgeon LR. HIV-associated oral lesions; immunologic, virologic and salivary parameters. J Oral Pathol Med. 1992;21:295-298.